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High-throughput sequencing 
enhanced phage display enables 
the identification of patient-
specific epitope motifs in serum
Anders Christiansen1, Jens V. Kringelum2, Christian S. Hansen2, Katrine L. Bøgh3, 
Eric Sullivan4, Jigar Patel4, Neil M. Rigby5, Thomas Eiwegger6, Zsolt Szépfalusi6, 
Federico de Masi2, Morten Nielsen2,7, Ole Lund2 & Martin Dufva1
Phage display is a prominent screening technique with a multitude of applications including 
therapeutic antibody development and mapping of antigen epitopes. In this study, phages were 
selected based on their interaction with patient serum and exhaustively characterised by high-
throughput sequencing. A bioinformatics approach was developed in order to identify peptide motifs 
of interest based on clustering and contrasting to control samples. Comparison of patient and control 
samples confirmed a major issue in phage display, namely the selection of unspecific peptides. The 
potential of the bioinformatic approach was demonstrated by identifying epitopes of a prominent 
peanut allergen, Ara h 1, in sera from patients with severe peanut allergy. The identified epitopes 
were confirmed by high-density peptide micro-arrays. The present study demonstrates that high-
throughput sequencing can empower phage display by (i) enabling the analysis of complex biological 
samples, (ii) circumventing the traditional laborious picking and functional testing of individual phage 
clones and (iii) reducing the number of selection rounds.
The concept of phage display was originally introduced in 19851 and is still one of the predominant 
techniques for the screening of protein-protein interactions. Phage display is based on libraries of phage 
particles expressing a great variety of exogenous peptides fused to phage surface proteins. The highly 
diverse library is reduced to a few leads by performing several rounds of selection, also known as bio-
panning2–5. Phage display has been widely applied in antibody discovery and has given rise to several 
therapeutic antibodies6–8. A range of different types of phage libraries have been constructed, with display 
of short random peptides or antibody domains as prominent examples2.
Phage display has been extensively used for the identification of antibody binding sites on antigens, 
known as epitope mapping2,9. Identification of epitopes is an important step in the development of diag-
nostic tools, in rational vaccine design and in identification of therapeutic targets10–13. Epitopes are gen-
erally classified as being either linear (continuous) or conformational (discontinuous). Whereas linear 
epitopes comprise short stretches of consecutive amino acid residues of the primary antigen sequence, 
conformational epitopes consist of residues that are distant in the primary sequence, but are brought 
close by the conformational folding of the native protein9.
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A prominent issue in phage display is the unintended selection of peptides that do not bind the target 
of interest, collectively known as “target unrelated peptides” (TUPs)14,15. Generally, TUPs either bind a 
constant part of the screening platform or provide the phage with a proliferation advantage. Constant 
parts of the screening platform include the solid phase (such as plastic or beads) as well as constant 
parts of antibodies or other capturing molecules14,15. A routine step in phage display is the amplification 
in bacteria. During this process, a pool of phages propagates in parallel and even minor proliferation 
advantages can have a profound impact on the output after this step. As a consequence, library diversity 
is shaped by selection as well as amplification, as thoroughly discussed by Derda et al.16. One way to deal 
with the TUP issue is to compare phage clones isolated in an experiment with databases encompassing 
previously isolated peptides and known TUP motifs17,18.
Today, the emergence of high-throughput sequencing techniques19 is transforming multiple areas (e.g. 
immune repertoire characterization20) and is well suited for analysis of the inherent diversity of phage 
libraries. The data output from deep sequencing should enable the analysis of highly complex samples 
by phage display and holds the potential to circumvent the traditional laborious picking and functional 
testing of individual phage clones. Accordingly, in recent years there have been considerable efforts in 
coupling high-throughput sequencing with phage display. Initially, the potential of this approach was 
demonstrated by studying protein interactions in a high-throughput manner21–23 followed by studies of 
antibody display libraries24–28. Recently, a gene-specific library was used to identify immunodominant 
regions of a vaccine antigen29. With regard to random peptide display libraries, an initial study that 
examined the overlap in peptides obtained by conventional versus high-throughput sequencing coupled 
phage display30 has been followed by a few others. One study used deep sequencing to assist the identifi-
cation of TUP candidates with a propagation advantage31. Two other studies employed high-throughput 
sequencing to identify peptides that bound to cell surfaces32,33. However, even though a major application 
of phage display is in epitope mapping, until now the potential of using high-throughput sequencing 
enhanced phage display for epitope mapping has only been described to a limited degree. Ryvkin et al. 
demonstrated that a fraction of the peptides obtained after binding to IgG from a pool of HIV positive 
sera could be aligned to an HIV protein thus indicating some HIV specificity34. Liu et al. took a broader 
approach and searched for putative IgG binding targets using BLASTP to determine the similarity between 
isolated phage peptides and all known proteins35. They established the approach on immunised mice as 
well as a sample from a human melanoma patient. These studies have been very limited with regards 
to the amount of human patient material and suggested epitopes have not been validated. Nonetheless, 
these studies encourage further investigations of the potential of high-throughput sequencing-assisted 
epitope mapping directly on serum.
In this study, we exploit the enormous data output of high-throughput sequencing to investigate 
samples of great complexity, specifically serum samples from patients with severe peanut allergy. Peanut 
allergy is regarded as one of the most serious forms of food allergy, in terms of prevalence, persistency 
and severity36,37 and Ara h 1, which is the focus of this study, is one of the major peanut allergens36–38. We 
present a general approach to address the issues of TUPs, identify patient-specific epitope motifs directly 
from serum, and validate identified epitopes using high-density peptide micro-arrays.
Results
Deep sequencing of phage libraries selected against patient serum. The phage selection pro-
cess (see Fig. 1) was based on the Ph.D.7TM phage library, which displays 7-mer peptides. This library has 
a reported diversity of 109, approaching the theoretical diversity (1.28 × 109), thus covering the majority 
of possible amino acid combinations. The phage particles were selected over 3 rounds of biopanning 
against IgE from 12 subject samples, comprising both patients with severe peanut allergy as well as 
control subjects with no reactivity towards peanut allergens. Specifically, the samples were sera from 4 
patients (P1-4) and 4 controls (C1-4) as well as plasma from 2 of these patients (P1 and P4) and 2 of 
the controls (C2p and C3p). In order to investigate whether there were changes in the epitope patterns 
over time, the plasma samples from the 2 patients (P1_12 and P4_12) were obtained about 9 years after 
the serum samples (P1 and P4). Epitope mimicking peptides were selected by competitive addition of 
Ara h 1. Following PCR amplification the phage DNA was sequenced by high-throughput sequencing. 
For every one of the 12 samples, DNA was obtained for all 3 selection rounds and subjected to deep 
sequencing.
For each of the 36 sampled conditions an average of 308,235 (standard deviation (sd) = 102,719) 
DNA sequences were obtained. Of these, an average of 231,642 (sd = 104,649) could be converted to 
peptide sequences. Identified peptides were further processed by removing peptides originating from 
DNA sequences with low quality and not having the NNK codon structure encoded in the phage library. 
Due to the high prevalence (e.g. > 100,000 copies) of some DNA sequences, derivate sequences (differing 
in 1 or 2 bases) were frequently observed and removed together with sequences identified as spill-over 
from one sample to another due to sequencing errors in barcodes (see Materials and Methods as well 
as Supplementary Fig. S1,S2). Nearly 50% of the initial DNA sequences were discarded in the filtering 
process resulting in 161,072 (sd = 82,792) peptides per condition on average. To diminish the effect of 
amplification bias as well as bias towards samples with high number of sequencing reads, the internal 
rank in each sample, and not the actual sequencing count, for each peptide were used in downstream 
analyses.
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Examination of the phage selection process. As peptide sequences were obtained for each selec-
tion round it was possible to monitor the change in peptide frequencies over the course of successive 
biopanning rounds. The total number of peptide sequences varied across samples, however, no corre-
lation with selection round was observed (Supplementary Table S2). However, the number of unique 
peptides in each sample decreased considerably with each subsequent selection round (Fig.  2A and 
Supplementary Fig. S3). For each sample an average of 89% (sd = 4%) of the peptides identified in round 
2 were also present in round 1, excluding peptides with a read count of 1. This was the case for 81% 
(sd = 9%) of the peptides when comparing round 3 with round 2. These observations indicated that the 
sequencing depth was adequate to identify the majority of the selected phages.
We also observed that from round 1 to 3 a few peptides had greatly increasing frequencies and ended 
up dominating each sample (Fig.  2B, Table  1, Supplementary Fig. S3 and Supplementary Table S5). 
There was a great overlap in the most frequent peptides from round 1 to 3, e.g. for the patient samples 
an average of 6 (range 4–7) of the ten most frequent peptides from round 1 were also observed after 
round 3. However, these dominating peptides were often also observed in control samples indicating that 
they were TUPs with a non-specific selection advantage. In fact, on average 6 out of the 10 most fre-
quent peptides in each selection round were also observed in the control samples (Supplementary Table 
S5). However, the general overlap in peptides between patient and control samples was much smaller 
(Fig. 3A). This indicates that the highly prevalent peptides are more likely to emerge in multiple samples, 
Figure 1. An overview of the phage selection process. (i) The IgE from serum is captured by beads coated 
with anti-IgE. The phage library is added and (ii) unbound phages are washed away. (iii) Negative selection, 
specifically incubation with SMP, is carried out to minimise unspecific binding. (iv) Phages expressing 
epitope mimicking peptides are eluted by competitive addition of Ara h 1. (v) The eluted phages are 
amplified in bacteria and either used for another selection round (starting at (i) again) or subjected to PCR 
and high-throughput sequencing.
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and hence be classified as TUPs. The most widespread peptide was the QLYREFN peptide, which was 
identified in 11 out of 12 samples. It is presented in Supplementary Table S6 alongside other TUP can-
didates to guide future phage display investigations.
Next, to extend the comparison of patient and control peptides beyond exact matches peptides were 
classified based on their similarity to other peptides. This was accomplished by pairwise alignment. The 
alignment threshold was established by doing 10 million random peptide comparisons, and using the 
99.999 percentile alignment score. Based on this threshold, a comparison of peptide similarity between 
patients and controls was made (Fig.  3B). A much higher degree of overlap was observed compared 
to the observations based on exact matches. This indicates that peptides with sequence similarity were 
frequent, and that similarity had to be taken into account in further analyses.
Identifying patient-specific peptide clusters. The next step was based on the hypothesis that 
selection of related peptides in multiple patients would represent key selection motifs that would be the 
main Ara h 1 epitope candidates. Peptides were clustered by pairwise alignment (Fig. 4). A p-value was 
derived by permutation of patient and control labels using a test statistic based on whether the peptides 
populating the cluster were derived from a patient sample or a control sample as well as their internal 
Figure 2. (A) A plot of the number of unique peptides identified in each patient sample for selection round 
1–3. In the first selection round an average of 1827 (sd = 642) unique peptides were obtained, dropping 
to 313 (sd = 150) and finally 170 (sd = 111) unique peptides after the second and third selection round, 
respectively. Results were similar for control samples as shown in Supplementary Fig. S3. (B) A stacked 
bar chart showing the combined frequency of certain rank intervals. Specifically, the frequency of the most 
frequent peptide (Top1) along with the combined frequencies of the peptides ranked 2–5, 6–20, 21–50,  
51–200 and below 200. The average of the combined frequencies for all patients is shown. Results were 
similar for control samples as shown in Supplementary Fig. S3.
Round 1 Round 2 Round 3
WSLSELH 14.3% VSRDTPQ 33.9% VSRDTPQ 73.1%
DGRYYIN 9.1% DGRYYIN 20.2% DGRYYIN 9.5%
VSRDTPQ 4.5% WSLSELH 15.8% WSLSELH 8.7%
MHTVAVQ 4.2% HWRLPLH 7.4% HLNQQNH 3.4%
HLNQQNH 3.5% HLNQQNH 4.6% HWRLPLH 0.9%
APRNVPP 2.4% IWRLPTH 4.2% IWRLPTH 0.7%
WPFHGDN 1.5% MHTVAVQ 2.4% SYTDLLR 0.7%
QISAASQ 1.5% VMPLDDV 1.4% VMPLDDV 0.5%
LPYDHLP 1.5% SYTDLLR 1.2% YPWFIRA 0.5%
YPWFIRA 1.4% YPWFIRA 0.9% MHTVAVQ 0.3%
Table 1.  The ten most frequent peptides and their frequencies for a sample patient, P1. The peptides are 
separated according to selection round (Round 1–3). The peptides with a grey overlay were also observed 
in a control sample with a prevalence >1. Similar top 10 tables for the other samples have been included in 
Supplementary Table S5.
www.nature.com/scientificreports/
5Scientific RepoRts | 5:12913 | DOi: 10.1038/srep12913
rank score. Accordingly, clusters that have multiple patient-specific peptides with a high rank, and where 
similar peptides could not be obtained in the control samples, would be provided with the lowest p-value. 
As such, the clustering approach takes the observed similarity between peptides from patient and control 
samples (Fig. 3B) into account. Interestingly, after statistical correction for the multiple testing problem 
(by Dunn-Bonferroni correction), a single statistically significant cluster stood out (p-value < 0.01) in 
selection round 2 and 3 (highlighted in Fig. 4A). In round 1 a patient-enriched cluster also had a low 
p-value, however, there were a large number of clusters in this round and the p-value was no longer sig-
nificant after correction for multiple testing. The number of peptides in the significant cluster were 28 in 
selection round 2 and 17 in round 3 (Supplementary Table S7). The patient samples contributed a differ-
ent number of peptides to the significant cluster (Supplementary Table S8). However, the patient sample 
P1 had most peptides in each of the clusters, specifically 46% and 47% of the peptides in the second and 
third selection round, respectively. P1, P3 and P4 contributed peptides to the significant clusters in both 
selection round 2 and 3. P1 and P4, which were investigated at two time points, contributed peptides at 
both time points. On the contrary, no peptides from P2 populated the significant clusters.
To examine which amino acid residues were the most conserved in the significant clusters, a sequence 
logo plot was made (Fig.  4B,C). Overall, the peptide motifs that appeared were highly similar. Closer 
inspection revealed that the amino acids W, P and H appeared particularly important.
Identifying epitope candidates. In order to investigate whether the selected peptide cluster matched 
the primary Ara h 1 protein sequence, thus suggesting a linear epitope, all peptides were aligned to the 
primary sequence of Ara h 1 (Fig. 5). Multiple patient-derived peptides aligned well around position 136. 
This was not the case for peptides derived from control samples as well as randomly generated peptides 
(Fig. 5). The amino acid sequence around this position was WRRPSH. The majority of the peptides with 
prominent alignment scores were part of the significant cluster identified in selection round 2 and 3 in 
Fig. 4.
Epitope validation on peptide arrays. To investigate the authenticity of the epitope suggested by 
alignment (Fig. 5), we investigated serum reactivity towards Ara h 1 on peptide micro-arrays. Overlapping 
12-mer peptides with a single offset covering the Ara h 1 sequence were synthesised in triplicates on the 
chip (a total of 1845 peptides). Binding of serum IgE to the peptides was then investigated (Fig. 6). Three 
out of four patients (P1, P3 and P4) showed distinct peaks of IgE reactivity at position 136 in Ara h 1, 
which is also where the peptides from the significant cluster aligned. These three patients were the same 
three patients that had peptides that aligned well to Ara h 1 at position 136 (Fig. 5) and populated the 
significant cluster (Fig. 4A). As such, the epitope suggested by clustering and alignment was confirmed 
by the peptide array observations. Both time points investigated for P1 and P4 demonstrated reactivity to 
the same epitope thus confirming the persistence suggested by the phage peptides. For the P2 patient no 
IgE reactivity was observed on the peptide array, and this patient did not contribute any peptides to the 
significant clusters. Similarly, no IgE reactivity was observed for control subjects (Supplementary Fig. S4).
Figure 3. (A) Venn diagrams showing the overlap in identical, unique peptides between patient samples 
(light circle) and controls (dark circle) for each selection round. The exact numbers have been included in 
the figure. (B) Venn diagrams showing the overlap in similar peptides between patient samples (light circle) 
and controls (dark circle) for each selection round. Similarity was determined by pairwise alignment using 
an alignment threshold established as the 99.999 percentile alignment score for 10 million random peptide 
comparisons. The specific numbers of peptides in each group have been included in the figure.
www.nature.com/scientificreports/
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Following the confirmation of the epitope authenticity the frequency of the peptides that enabled the 
epitope identification were re-examined. Overall, the peptides had low frequencies, which would have 
made them very difficult to detect by traditional Sanger sequencing of phage clones (Supplementary Fig. 
S5). Assuming that 1000 phage clones were screened, e.g. by ELISA, thereby detecting peptides with a 
frequency above 0.1%, only 6 and 7 out of 28 and 17 peptides in the significant clusters would have been 
detected in selection round 2 and 3, respectively. As a consequence, the identified epitope would have 
been missed for P4 in all selection rounds and also for P3 in the second selection round.
Discussion
Harnessing the power of high-throughput sequencing can improve phage display in a number of ways. 
First of all, the extensive data output enables the detection of rare phages in a larger population. This 
feature was used to detect antibody epitopes in polyclonal serum samples. It is worth noting that the IgE 
antibodies that target Ara h 1 only comprise a tiny fraction of the serum antibodies, given that IgE is 
a rare isotype compared to e.g. IgG39 and, further, only a fraction of the IgE consists of peanut-specific 
antibodies40. Nonetheless, Ara h 1 epitopes could be identified in the patients.
The bioinformatic pipeline presented here, which is based on clustering and contrasting with control 
samples, assisted the identification of a relevant peptide motif. It is worth emphasising that the clustering 
approach is very general, and multiple selection motifs could, in principle, be identified simultaneously. 
As such, the pipeline should be widely applicable in the analysis of multi-target mixtures in a variety of 
settings extending beyond epitope mapping to e.g. binding assays and cell surface analysis. Furthermore, 
Figure 4. (A) Plots of the summed rank value for clusters obtained by pairwise-alignment and separated 
according to selection round (1–3). The clusters are further separated based on whether the summed 
rank value derives from peptides identified in patients (x-axis) or controls (y-axis). 4624, 617 and 333 
clusters were identified in selection round 1, 2 and 3, respectively. One cluster in selection round 2 and 3 
was significantly enriched (p-value < 0.01) for patient-specific peptides and is coloured dark. (B) Peptide 
sequence logo plot of the significant cluster obtained in round 2 and highlighted in (A). The logo was made 
by constructing position-weighted Kullback Leibler logos of the multiple alignment of the cluster peptides, 
using the Seq2Logo webserver51. Height corresponds to the amount of information contained in a specific 
position. Large symbols represent frequently observed amino acids. Symbols are narrow if there were many 
gaps in the alignment at the position. The Seq2Logo default amino acid colour coding is used (DE residues 
are red, NQSGTY are green, RKH are blue and the remaining are black). (C) Similar to (B) but for the 
significant cluster in round 3.
www.nature.com/scientificreports/
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with regards to epitope mapping, partly due to the high diversity of the phage library (approximately 
109), the approach is not limited to mapping of linear epitopes. If a highly patient-specific motif emerged, 
that did not match the primary sequence of the target of interest, it could be a selection motif that mimics 
a conformational epitope.
Another promising observation in this study, is that a patient-specific motif could already be observed 
in early selection rounds, supporting the notion that deep sequencing will enable phage display exper-
iments with fewer, and ultimately, a single selection round. By performing fewer selection rounds the 
selection bias can be reduced which should diminish the loss of relevant sequences16,31,32. Hoen et al. 
have previously suggested the idea, however, they identified phages of interest based on persistence across 
selection rounds32. Similarly, other studies have identified peptides of interest based on enrichment 
through consequtive biopanning rounds33,41. These approaches are obviously only possible if multiple 
selection rounds are sequenced or, alternatively, a thorough (and expensive) sequencing of the naїve 
library could be sufficient. Motif identification represents an alternative approach, that could enable the 
identification of peptides of interest based on sequencing a single round.
Round 1
Round 2
Round 3
Patient Samples
Round 1
Round 2
Round 3
Control Samples
Figure 5. Alignment of patient-derived peptides (left) or control-derived peptides (right) to the 
primary sequence of Ara h 1. Peptides were mapped to Ara h 1 by aligning each peptide to overlapping 
7-mers from the Ara h 1 primary sequence using pairwise alignment. Each phage peptide was plotted at 
the starting position of the overlapping 7-mer that provided the best alignment score. The top row is a plot 
for the peptides from selection round 1, while the middle and bottom row are for selection round 2 and 3, 
respectively. Peptides that were part of a statistically significant cluster are emphasised as dark spots. The 
grey line represents a significance assessment which is the 99.99 percentile alignment scores obtained after 
aligning 1 million random peptides to each overlapping 7-mer. Alignments with a score below zero were 
discarded.
Figure 6. IgE reactivity of patients to Ara h 1as measured by peptide micro-arrays. The right-bound 
rolling median (window size 12) of the mean intensity of the triplicate 12-mer peptides overlapping each 
residue is shown for every patient sample. The start position of the identified epitope, position 136, has been 
specifically marked. For P2 no peaks were observed, whereas all the other samples showed a distinct peak at 
position 136.
www.nature.com/scientificreports/
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Interestingly, in this study the epitope was identified without the functional testing which is com-
monly part of traditional phage display. The colony picking, functional testing (e.g. by ELISA) and subse-
quent Sanger sequencing of positive clones is a very laborius element in phage display9,42. By omitting the 
functional step and performing fewer selection rounds, we suggest that the throughput of phage display 
can be increased, as multiple complex samples can be tested in parallel.
Deep sequencing of the phage output after each selection round enabled a thorough examination of 
the selection process. The general trends were highly consistent across samples. With each round fewer 
unique peptides were obtained; decreasing from thousands after the first round to a few hundred after 
three rounds. This observation is in line with the expected process of affinity selection, wherein the spec-
ificity of the phage-libraries increases with additional biopanning rounds while the diversity drops16,43.
There was a great overlap among the most frequent peptides across selection rounds. However, recur-
ring peptides with high frequencies could also be observed in control samples indicating that they were 
TUPs. This finding suggests that consistently prevalent peptides identified in other studies32,34 might be 
TUPs, which would explain why they did not match the target. Along these lines, many phage exper-
iments have likely been discarded, or demanded laborious optimisation, because the only hits identi-
fied were irrelevant. The prevalence of TUPs was further suggested by the observation that the peptide 
overlap between paired samples obtained at two time points were similar to the overlap to other patient 
samples (for the paired samples the median Tanimoto coefficient for unique peptides was 0.6% and 0.5% 
for the matching pair and 0.8% and 0.4% for the overlap to the remaining patient samples for P1 and 
P4, respectively).
Derda et al. recently identified hundreds of peptides with proliferation advantages, so-called ‘para-
sitic’ TUP peptides, in the Ph.D.-7TM library31. We did not observe any overlap between the peptides we 
obtained, and the reported parasitic TUPs. We speculate that selection criteria and experimental context 
(such as library type and batch) vary greatly between phage experiments and have an extensive impact on 
which TUPs will be selected. The high number of TUPs we observed, most of which were not previously 
reported, demonstrates how critical it is to filter out these sequences. As a result, we suggest including 
parallel control experiments to identify putative TUPs in future experimental setups. Until TUP data-
bases17,18 have become more comprehensive, it seems to be the optimal way to take into account the 
distinct differences between selection schemes. It is worth noting that careful experimental design could 
allow parallel analysis of two or more conditions of interest, with one acting as control for the others 
and vice versa. This may not be feasible for all setups, but would omit the need to include a condition, 
that only provides information on TUPs.
Possibly due to the sample complexity a great variety of peptides were observed in the output. Selection 
of related peptides across patients represented key selection motifs that assisted the epitope identifica-
tion. The alignment threshold used in the clustering process was determined based on simulations with 
randomly generated peptides. The threshold was relatively conservative and could have been varied to 
increase or decrease alignment stringency. A consequence of the conservative threshold is that relevant 
sequences may be missed. The importance of the threshold level is underlined by the observation that 
some patient samples had very few peptides in the significant cluster and if the alignment threshold had 
been slightly more restrictive, the epitope might have been overlooked. The fact that we observe peptides 
of high similarity that can be clustered and form motifs underlines the importance of taking similar 
peptides into account instead of focusing only on identical matches. Importantly, this also applies for 
TUPs, where excluding peptides with exact matches in control samples, such as it has previously been 
done35, may not be sufficient. The bioinformatic approach we have presented solves this issue, since TUP 
sequences from patients would cluster with similar peptides obtained in control samples. Consequently, 
even when there are no exact matches between a patient peptide and a control peptide, clustering of 
patient peptides with similar control peptides would result in a mixed cluster that would be disregarded 
due to its p-value. Alternative clustering approaches are available for the identification of peptide motifs 
in large-scale data, such as MUSI44. However, MUSI does not contrast the results with control samples 
and, furthermore, duplicate copies of the same sequence are removed. We suggest that the prevalence 
of the peptides has some correlation with the importance of the peptides and, accordingly, we employ a 
rank score in our analyses.
Deep sequencing of phage libraries introduced some inherent issues that had to be addressed. Highly 
prevalent DNA sequences gave rise to derivative sequences due to sequencing errors (Supplementary 
Fig. S1) as previously reported by Matochko et al.31. We further observed that, as samples were multi-
plexed for deep sequencing, highly prevalent DNA sequences consistently turned up with low counts in 
other samples on the same sequencing chip (Supplementary Fig. S2). This is presumably due to errors 
in sequencing of the sample barcode. It is of vital importance for later alignment and clustering that 
derivative sequences (both internal ‘mutations’ and cross-sample ‘spill-over’) are eliminated. Otherwise, 
peptides could be assigned to the wrong sample, which could hinder TUP identification, and highly 
prevalent peptides would give rise to clusters, that were derived from artificial sequences. The issue with 
derivative sequences, which is inherent to any deep sequencing study where some DNA sequences have a 
very high prevalence, would clearly benefit from studies dedicated to describing and solving these issues.
There was an extensive overlap in the epitope mapping results for individual samples from phage dis-
play compared to peptide micro-arrays. Specifically, the samples that had peptides mimicking the Ara h 
1 epitope were also the samples where this epitope could be identified on the peptide micro-array. This 
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suggests that both techniques generate reproducible results of considerable accuracy. Interestingly, the 
identified epitope appeared to be persistent, since it could be identified by phage display as well as pep-
tide micro-arrays in samples obtained with a 9 year interval. Of note, the identified epitope is included 
in a previously described epitope hotspot of Ara h 136,45. A previous study, based on conventional phage 
display, further suggested conformational Ara h 1 epitopes46, however, no such motifs were identified in 
the present study. For patient P2 no epitopes were identified by phage display or peptide micro-arrays. 
This patient had a low level of specific IgE and we speculate that the methods were not sensitive enough 
to identify any epitopes or that the sample quality was low.
The coupling of phage display with high-throughput sequencing offers several advances to conven-
tional phage display. First of all, the large data output provides an opportunity to perform in-depth 
studies of the phage selection process and also permits the identification of rare phages in a large popu-
lation. This should improve knowledge of the parameters that affect phage selection and enable the study 
of multi-target samples. Here, a general bioinformatic approach has been presented, which identifies 
selection motifs of interest. The observed prevalence of TUPs demonstrated the necessity of examining 
parallel control samples, which were used as a contrast in the clustering approach. Relevant selection 
motifs could be identified in early selection rounds and without laborious functional screening. The 
increased throughput combined with the in-depth data output holds the promise to expand the use of 
phage display to new applications.
Methods
Peanut allergic patient samples. Sera from 4 peanut allergic adults (P1-4) and 4 peanut-toler-
ant control subjects (C1-4) were analysed alongside plasma from 4 of these individuals (P1_12, P4_12, 
C2p and C3p). The 2 patient plasma samples (P1_12 and P4_12) were obtained about 9 years after the 
patient sera samples. The 4 patients had a convincing history of peanut-related anaphylaxis according to 
WAO guidelines47. All samples were tested for peanut extract-specific IgE by ImmunoCAP and Ara h 
1-specific IgE by ELISA. No Ara h 1-IgE reactivity was observed for the control samples. The protocol 
was approved by the local Ethical Committee of the Medical University of Vienna and written informed 
consent was obtained (protocol no. EK 428/2008). The samples were treated in accordance with the 
approved guidelines.
Selection of Ara h 1 mimicking peptides. Figure 1 provides an overview of the selection process. 
In brief, 12 × 200 μ L (6 mg) of M-280 tosylactivated Dynabeads (Invitrogen) were coated with 10 μ g pol-
yclonal rabbit anti-human IgE (DAKO, A0094) for 48 h at 37 °C, and blocked with 0.5% skimmed milk 
powder (SMP) in Phosphate Buffer Saline (PBS). Patient serum (500 μ L) or plasma (1,300 μ L) was diluted 
in PBS with 0.5% SMP and 0.05% Tween 20, and incubated overnight at 4 °C with 200 μ L of the coated 
bead suspension. After extensive washing, 50 μ L of the coated beads were used immediately for the first 
round of selection, while the remaining 150 μ L were stored for later selection rounds.
In the first selection round 50 μ L beads with immobilized IgE were blocked in 1 mL of 2% SMP in 
PBS for 1 h at room temperature and washed extensively. The beads were then incubated overnight at 4 °C 
with 10 μ L (~2 × 1011) phages from a library of phages displaying random heptamer peptides (Ph.D.-7TM, 
New England BioLabs). This was followed by extensive washing and negative selection; specifically 1 h 
incubation in 10 mL PBS with 0.5% SMP and 0.05% Tween 20 and 8 washing steps each consisting of 
10 min incubation in 10 mL PBS with 0.05% Tween 20. Next, phages of interest were eluted by adding 
25 μ g Ara h 1 protein. The Ara h 1 was purified as previously described by Bøgh et al.48. The purity of 
Ara h 1 was confirmed by reverse phase high-performance liquid chromatography to be > 99%. Size 
exclusion chromatography demonstrated that the Ara h 1 was present as a trimer. Eluted phages were 
amplified by direct infection of ER2738 Escherichia coli cells (New England Biolabs). Phage amplification 
was done at 37 °C for 4.5 hours. Amplified phages were precipitated using PEG/NaCl and titered. The 
second and third selection rounds were carried out in an identical way, using ~2 × 1011 of the phages 
selected in the previous round.
High-throughput Sequencing. Amplified phage eluates from each of the 3 selection rounds were 
subjected to PCR using the Phusion High-Fidelity DNA polymerase (New England Biolabs). To mitigate 
PCR bias, the PCR reactions were carried out in triplicates and the number of cycles was limited to 25. 
The PCR was carried out as recommended by the manufacturer, using 25 μ L reactions with 1 μ L 1:10 
diluted phage eluates as template and an annealing temperature of 55 °C. The variable part of the phage 
library was specifically amplified using barcoded primers (Supplementary Table S1). The corresponding 
PCR fragment was extracted from a 2% agarose gel using the Qiaquick Gel Extraction Kit (Qiagen). The 
triplicate PCR reactions were pooled prior to the gel extractions. The DNA concentration was deter-
mined using a Qubit fluorometer (Life) and the fragment size was confirmed using a 2100 Bioanalyzer 
(Agilent) following manufacturer’s protocol.
Next, sequencing adaptors were ligated onto the DNA fragments using the Ion Plus fragment library 
kit (Life), and the fragment size and concentration was confirmed using a Bioanalyzer (Agilent) and 
Qubit fluorometer (Life), respectively. Subsequently, the DNA fragments were attached to Ion Sphere 
Particles (ISPs) and amplified by emulsion PCR according to the Ion OneTouch 200 protocol. The ISPs 
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were loaded onto an Ion 316 chip and sequenced on an Ion Torrent PGM using the Ion Torrent sequenc-
ing kit 200 v2, as described by the manufacturer.
Converting sequencing reads to peptides and quality filtering. DNA reads obtained from the 
sequencing was first filtered by sample barcodes. Reads that did not match any of the barcodes, both 
forward and reverse complement, were removed. The DNA reads were then translated in all six reading 
frames and aligned to the protein regions of the phage protein that flank the displayed 7-mer peptide 
using the BLAST algorithm49. Then 7-mer peptides and their originating DNA sequences were extracted 
from reads that produced meaningful alignments; i.e. the protein sequence aligned to both flanking 
regions with a 7-mer peptide gap.
The peptides were further processed by i) removing peptides where at least 1 DNA base pair (bp) 
coding for the peptide were assigned a Phred quality score below 20 and ii) removing reads where the 
DNA sequence did not match the NNK-codon pattern intrinsic to the Ph.D.-7TM phage library (N = any 
nucleotide, K = G or T).
Some sequences had a very high prevalence within a sample. A consequence of high-throughput 
sequencing read errors19,31 could be that such abundant sequences might artificially give rise to similar 
sequences with a low abundance, differing from the abundant sequence at 1 or 2 positions. In fact, a lin-
ear relationship was observed between the prevalence of abundant sequences and the prevalence of sim-
ilar “derivative” sequences (Supplementary Fig. S1). This suggests that the derivative peptides are indeed 
read error variations of the abundant peptide. As a result, sequences that were at least 500 or 10,000 
times less prevalent than a similar (high abundant) sequence in the same sample, differing by just one 
or two base pairs, respectively, were removed. These conservative thresholds were established to ensure 
the relevance of the detected peptides. Furthermore, when two subjects were analysed on the same Ion 
Torrent chip, highly abundant sequences in one patient were sometimes observed with a low prevalence 
in the other subject. The relationship in prevalence was, once again, linear and such relationship could 
not be observed across different sequencing chips (Supplementary Fig. S2). The derivative sequences 
likely originate from sequencing errors in the barcode sequence leading to a mislabelling of the sample. 
To avoid this issue, peptides of low abundance were removed if they were also observed with at least 100 
times higher prevalence in the other subject tested on the same Ion Torrent chip. Finally, the obtained 
peptides were compared to a list of “parasitic” phages with a suspected proliferation advantage31, how-
ever, no overlap was observed and no peptides were removed. An overview of the number of reads that 
passed each step of quality filtering can be found in Supplementary Table S2-4.
Peptide clustering. To remove bias towards samples with a higher number of sequencing reads, each 
unique peptide in a sample was assigned a normalised rank score based on the following formula:
r
R
N
100 100 1i
i= − × ( )
Here Ri is the rank of peptide i within a specific sample. Peptides with the same prevalence were given an 
average rank score. As a result of the above conversion, the most prevalent peptide in each sample will 
be given a rank score of 100, and the least prevalent peptide will have a rank score of 0. The rank values 
were summed across samples and used for sorting peptides prior to clustering.
Peptides of each sample were clustered according to the Hobohm I algorithm using pairwise align-
ment as distance function50 and an alignment score threshold of 31. The alignment threshold of 31 was 
established as the 99.999 percentile of 10 million pair-wise alignments of random peptides, using a stand-
ard Smith-Waterman alignment algorithm (using BLOSUM50, gap-opening and extension penalties of 5 
and 1, respectively, and a minimum alignment length of 6). This alignment threshold was also used for 
an overall comparison of the peptides in patient and control samples.
To establish patient-related significance each cluster was analysed by patient-control contrasting. The 
difference, t, between summed rank-scores, ri, assigned to patients and controls within a single cluster 
were calculated and used as test-statistic. The null-hypothesis assumes that the test statistic would be 
equal or higher to that of random clusters established by permutation, i.e. shuffling the patient-control 
labels 10,000 times. A p-value of the observed test-statistic was calculated as the number of random clus-
ters having a lower test-statistic divided by the number of permutations (10,000), as shown in Equation 2:
=
( < )
( )p
N t t
N 2
true permutated
The null-hypothesis was rejected for clusters with a p-value lower than 0.01/n where n is the number 
of clusters formed. Hence, such clusters had a significant patient-control contrast and were assumed to 
be obtained from allergen-specific selection.
Representing significant clusters by sequence motifs. Cluster motif visualisation was done by 
constructing position-weighted Kullback Leibler logos of the multiple alignment of the cluster peptides, 
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using the Seq2Logo webserver51. The multiple alignment was performed using a MAFFT-incorporating 
Needleman-Wunsch global pairwise alignment algorithm using 1,000 cycles of iterative refinement for 
increased accuracy.
Aligning peptides to the Ara h 1 sequence. Peptides that were selected from the phage libraries 
were mapped to Ara h 1 by aligning each peptide to overlapping 7-mers from the Ara h 1 primary 
sequence (Uni-prot ID: P43238) using the same alignment parameters as for the peptide clustering. Each 
phage peptide was assigned the starting position of the overlapping 7-mer that provided the best align-
ment score. Alignments with a score below zero were discarded. The significance of alignment scores 
was assessed by aligning 1 million random peptides to each overlapping 7-mer and reporting the 99.99 
percentile of the alignment scores.
High-density peptide micro-arrays. A peptide library was generated in silico for synthesis on 
high-density peptide micro-arrays. The library consisted of single-offset overlapping 12-mer peptides 
covering the primary sequence of Ara h 1 (Uni-prot ID: P43238) in triplicates (1845 peptides). Peptide 
synthesis was accomplished by light-directed array synthesis in a Roche-NimbleGen Maskless Array 
Synthesizer (MAS) using an amino functionalised substrate coupled with 6-amino hexanoic acid as a 
spacer and amino acid derivatives carrying a photosensitive 2-(2-Nitrophenyl) propyl-oxy-carbonyl-group 
(NPPOC). Coupling of amino acids was done using pre-activated amino acid with activator (HOBT/
HBTU) and Ethyl-di-iso-propylamine in DMF for 5–7 minutes before flushing the substrate. Cycles 
of coupling were repeated until 12-mer peptides were synthesized. Intermediate washes on the arrays 
were done with N-Methyl-2-pyrrolidone (NMP) and site-specific cleavage of the NPPOC group was 
accomplished by irradiation of an image created by a Digital Micro-Mirror Device (Texas Instruments, 
SXGA + graphics format), projecting light with a 365 nm wavelength. Final de-protection to cleave off 
the side-chain protecting groups of the amino acids was done with Trifluoroacetic acid(TFA)/Water/
Triisopropylsilane for 30 minutes. The final micro-arrays were incubated overnight at 4 °C with individ-
ual sera mixed with binding buffer in a 1:5 dilution in a final volume of 20 μ L. This was followed by 
incubation with goat anti-Human IgE conjugated with tetramethylrhodamine (TRITC) (Life, A18798) at 
room temperature for 3 hours. Serum from P1 and P3 were also evaluated in a 1:2 dilutions with binding 
buffer. Finally, the arrays were scanned using a MS200 microarray scanner, and signals were extracted 
using NimbleGen DEVA signal extraction software.
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